

Cell and Gene Therapy Manufacturing Services Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

Market Report | 2024-08-02 | 114 pages | Global Market Insights

AVAILABLE LICENSES:

- Single User \$4850.00
- Multi User \$5350.00
- Enterprise User \$8350.00

Report description:

Cell and gene therapy manufacturing services market size is set to record an 18.9% CAGR during 2024-2032 driven by rapid advancements in biotechnology and the increasing prevalence of genetic disorders and chronic diseases. As innovative therapies for conditions like cancer, genetic disorders, and rare diseases continue to emerge, there is a growing demand for specialized manufacturing services to produce high-quality, customized cell and gene therapies.

Pharmaceutical companies, biotech firms, and research institutions are increasingly outsourcing their manufacturing needs to specialized service providers to scale up production and ensure compliance with stringent regulatory standards. For instance, in April 2024, Memel Biotech introduced a comprehensive service for advanced therapy development and manufacturing. The complexity of cell and gene therapies also necessitates sophisticated manufacturing processes, which drives demand for expertise and infrastructure provided by dedicated service providers.

The overall industry is divided into type, mode, indication, end user, and region.

Based on type, the cell and gene therapy manufacturing services market from the gene therapy segment is expected to generate notable revenue by 2032. This is due to its innovative approach in treating genetic disorders and diseases at a molecular level. As gene therapy progresses with advanced techniques, such as CRISPR and viral vector-based methods, the need for specialized manufacturing services to produce these complex therapies has increased.

In terms of end user, the cell and gene therapy manufacturing services market value from the hospitals segment is projected to observe a robust CAGR from 2024 - 2032. This is owing to the increasing adoption of advanced therapies for patient treatment within hospital settings. As hospitals expand their capabilities to offer cutting-edge treatments for complex diseases, they rely on specialized manufacturing services to provide high-quality, customized cell and gene therapies.

Asia Pacific cell and gene therapy manufacturing services industry size will grow between 2024 and 2032 driven by the increasing prevalence of genetic and chronic diseases, coupled with significant advancements in biotechnology. The expanding healthcare infrastructure and growing investments in R and D activities are enhancing the capabilities for producing sophisticated cell and gene therapies. The supportive government policies and incentives aimed at fostering innovation and improving healthcare outcomes are also contributing to regional market expansion.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Table of Contents:

Report Content

Chapter 1 Methodology and Scope

- 1.1 Market scope and definitions
- 1.2 Research design
 - 1.2.1 Research approach
 - 1.2.2 Data collection methods
- 1.3 Base estimates and calculations
 - 1.3.1 Base year calculation
 - 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
 - 1.5.1 Primary sources
 - 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360 synopsis

Chapter 3 Industry Insights

- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
 - 3.2.1 Growth drivers
 - 3.2.1.1 Increasing prevalence of cancer and other diseases
 - 3.2.1.2 Increasing government grants and support for development of cell and gene therapies
 - 3.2.1.3 Increasing pharmaceutical R and D spending
 - 3.2.2 Industry pitfalls and challenges
 - 3.2.2.1 High risk of mutagenesis
 - 3.2.2.2 Lack of standardized production systems for cell and gene therapy products
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
 - 3.4.1 U.S.
 - 3.4.2 Canada
 - 3.4.3 Europe
- 3.5 Technology landscape
- 3.6 Pipeline analysis
- 3.7 Porter's analysis
- 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

- 4.1 Introduction
 - 4.1.1 Thermo Fisher Scientific Inc.
 - 4.1.2 Boehringer Ingelheim International GmbH
 - 4.1.3 Merck KGaA
- 4.2 Company market share analysis
- 4.3 Competitive analysis of major market players
- 4.4 Company matrix analysis
- 4.5 Vendor matrix analysis
- 4.6 Competitive positioning matrix
- 4.7 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2018 - 2032 (\$ Mn)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.1 Key trends
- 5.2 Cell therapy
 - 5.2.1 Allogenic
 - 5.2.1.1 Mesenchymal stem cells
 - 5.2.1.2 T-cells
 - 5.2.1.3 Natural killer cells
 - 5.2.1.4 Hematopoietic stem cells
 - 5.2.1.5 Other allogeneic cells
 - 5.2.2 Autologous
 - 5.2.2.1 Mesenchymal stem cells
 - 5.2.2.2 T-cells
 - 5.2.2.3 Natural killer cells
 - 5.2.2.4 Hematopoietic stem cells
 - 5.2.2.5 Other allogeneic cells
- 5.3 Gene therapy
 - 5.3.1 Viral vectors
 - 5.3.2 Non-viral vectors

Chapter 6 Market Estimates and Forecast, By Mode, 2018 - 2032 (\$ Mn)

- 6.1 Key trends
- 6.2 Contract manufacturing
- 6.3 In-house manufacturing

Chapter 7 Market Estimates and Forecast, By Indication, 2018 - 2032 (\$ Mn)

- 7.1 Key trends
- 7.2 Oncology diseases
- 7.3 Cardiovascular diseases
- 7.4 Orthopedic diseases
- 7.5 Infectious diseases
- 7.6 Ophthalmology diseases
- 7.7 Other indications

Chapter 8 Market Estimates and Forecast, By End user, 2018 - 2032 (\$ Mn)

- 8.1 Key trends
- 8.2 Biopharmaceutical companies
- 8.3 Academic research institutes
- 8.4 Hospitals

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 (\$ Mn)

- 9.1 Key trends
- 9.2 North America
 - 9.2.1 U.S.
 - 9.2.2 Canada
- 9.3 Europe
 - 9.3.1 Germany
 - 9.3.2 UK
 - 9.3.3 France
 - 9.3.4 Spain
 - 9.3.5 Italy
 - 9.3.6 Rest of Europe
- 9.4 Asia Pacific

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 Rest of Asia Pacific
- 9.5 Latin America
 - 9.5.1 Brazil
 - 9.5.2 Mexico
 - 9.5.3 Rest of Latin America
- 9.6 Middle East and Africa
 - 9.6.1 South Africa
 - 9.6.2 Saudi Arabia
 - 9.6.3 Rest of Middle East and Africa

Chapter 10 Company Profiles

- 10.1 Boehringer Ingelheim International GmbH
- 10.2 Bluebird Bio, Inc.
- 10.3 Catalent, Inc.
- 10.4 Charles River Laboratories International, Inc.
- 10.5 Merck KGaA
- 10.6 Miltenyi Bioindustry (Miltenyi Biotec)
- 10.7 Samsung Biologics
- 10.8 Takara Bio Inc.
- 10.9 Thermo Fisher Scientific Inc
- 10.10 WuXi AppTec Co., Ltd.

□

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Cell and Gene Therapy Manufacturing Services Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

Market Report | 2024-08-02 | 114 pages | Global Market Insights

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4850.00
	Multi User	\$5350.00
	Enterprise User	\$8350.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-05"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

